相关实验视频

Updated: May 14, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

患有过渡细胞癌的狗的治疗结果

Ka To Chu¹, Omid Nekouei², Antonio Giuliano^1,3

¹Veterinary Medical Centre, City University of Hong Kong, Kowloon, Hong Kong SAR, China.

Frontiers in veterinary science

|May 12, 2025

概括

计量化学疗法显著改善了患有过渡细胞癌 (TCC) 的狗的生存时间,这是一种常见的尿路癌症. 这种治疗耐受性很好,为犬类TCC管理提供了有前途的选择.

科学领域:

兽医瘤学兽医瘤学
狗癌症研究狗癌症研究
泌尿器细胞癌的癌症.

背景情况:

过渡性细胞癌 (TCC) 是狗中最常见的尿路癌.
狗TCC的预后往往很差,没有确立的标准治疗.
了解治疗对生存的影响对于犬类TCC患者至关重要.

研究的目的:

描述TCC的狗的临床结果.
评估瘤位置对存活率的影响.
确定各种治疗方式对TCC患者存活率的影响.

主要方法:

追溯分析84只被诊断患有TCC的客户拥有的狗.
来自香港一家大型兽医医院 (2005-2024) 的数据.
通过不同瘤位置和治疗 (手术,化疗,COX-2抑制剂) 的生存时间的比较.

主要成果:

总体中位生存时间为233天,58.3%的狗死亡或安乐死.
前列腺瘤与最短的中位生存期 (88天) 有关.
计量化学疗法导致显著更长的存活期 (303天) 和更少的不良事件.

结论:

计量化学疗法,特别是ambucil,提供了良好的耐受性和有效的治疗犬类TCC.
这种方法可以作为独立治疗或作为常规化疗的辅助方法.
对狗的最佳TCC治疗策略进行进一步的研究是有必要的.

关键词:

这就是TCC TCC.狗类犬类动物狗类犬类 ambucil 是一种.计量化学疗法计量化学疗法过渡细胞癌的过渡细胞癌.尿膀质量尿膀质量

更多相关视频

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats

Published on: October 24, 2016

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.